The development of new classes of antimicrobial is urgently needed due to the widespread occurrence of multi-resistant pathogens. In this study, three novel ruthenium complexes: [Ru(dmob)₂(BTPIP)](PF₆)₂ (Ru(II)-1), [Ru(dbp)₂(BTPIP)](PF₆)₂ (Ru(II)-2), and [Ru(dpa)₂(BTPIP)](PF₆)₂ (Ru(II)-3) (dpa = 2,2’-dipyridylamine, dmob = 4,4’-dimethoxy-2,2’-bipyridyl, dbp = 4,4’-di-tert-butyl-2,2’-dipyridyl, BTPIP = 4-(benzo[b]thiophen-2-yl)phenyl-1H-imidazo[4,5-f][1,10]phenanthroline) are synthesized and investigated as antimicrobial metallodrugs. We demonstrate that all three complexes have significant antimicrobial activity against Staphylococcus aureus by testing their minimal inhibitory concentrations = 0.0015–0.0125 mg/mL. The antibacterial activity of the best active complex Ru(II)-3 is 13 times that of ofloxacin (minimal inhibitory concentration = 19.5 μg/mL). Importantly, Ru(II)-3 not only increases the susceptibility of Staphylococcus aureus to existing common antibiotics but also shows noticeably delayed and decreased resistance in Staphylococcus aureus since the minimal inhibitory concentration values of Ru(II)-3 only increased eightfold times after 20 passages. Furthermore, the biofilms formation and rabbit erythrocyte hemolysis assays verified that Ru(II)-3 also efficiently inhibit the biofilm formation and toxin secretion of Staphylococcus aureus.

Search results

The development of three ruthenium-based antimicrobial metallodrugs: Design,synthesis,and activity evaluation against Staphylococcus aureus

Metal-based Drugs